Cargando…
Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
BACKGROUND: γ9δ2T cells, which express Vγ9 and Vδ2 chains of the T cell receptor (TCR), mediate cancer immune surveillance by sensing early metabolic changes in malignant leukemic blast and not their healthy hematopoietic stem counterparts via the γ9δ2TCR targeting joined conformational and spatial...
Autores principales: | Johanna, Inez, Straetemans, Trudy, Heijhuurs, Sabine, Aarts-Riemens, Tineke, Norell, Håkan, Bongiovanni, Laura, de Bruin, Alain, Sebestyen, Zsolt, Kuball, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419469/ https://www.ncbi.nlm.nih.gov/pubmed/30871629 http://dx.doi.org/10.1186/s40425-019-0558-4 |
Ejemplares similares
-
Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
por: Johanna, Inez, et al.
Publicado: (2021) -
Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model
por: Braham, Maaike V. J., et al.
Publicado: (2018) -
Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
por: Kierkels, Guido J.J., et al.
Publicado: (2021) -
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021) -
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
por: Straetemans, Trudy, et al.
Publicado: (2018)